PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of procrsmedFormerly medchtJournal of the Royal Society of MedicineProceedings of the Royal Society of Medicine
 
Proc R Soc Med. 1962 June; 55(6): 480–484.
PMCID: PMC1896661

MER-29 (Triparanol) in the Control of Hypercholesterolæmia

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (705K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • AVIGAN J, STEINBERG D, VROMAN HE, THOMPSON MJ, MOSETTIG E. Studies of cholesterol biosynthesis. I. The identification of desmosterol in serum and tissues of animals and man treated with MER-29. J Biol Chem. 1960 Nov;235:3123–3126. [PubMed]
  • BLOHM TR, KARIYA T, MACKENZIE RD. Excretory products of the sterol biosynthetic pathway in the MER-29-treated rat. Excretion of MER-29. Prog Cardiovasc Dis. 1960 May;2:519–523. [PubMed]
  • CORCORAN AC. Coronary atherosclerosis status of MER-29 (triparanol). Am Heart J. 1961 Apr;61:431–435. [PubMed]
  • ESTES JE. Clinical experience with MER-29, an inhibitor of cholesterol synthesis. Prog Cardiovasc Dis. 1960 May;2:564–570. [PubMed]
  • FRANTZ ID, Jr, MOBBERLEY ML, SCHROEPFER GJ., Jr Effects of MER-29 on the intermediary metabolism of cholesterol. Prog Cardiovasc Dis. 1960 May;2:511–518. [PubMed]
  • HALPERIN MH. A clinical study of MER-29 in patients with angina pectoris. Prog Cardiovasc Dis. 1960 May;2:631–636. [PubMed]
  • HOLLANDER W, CHOBANIAN AV, WILKINS RW. The effects of triparanol (MER-29) in subjects with and without coronary artery disease. JAMA. 1960 Sep 3;174:5–12. [PubMed]
  • JOSE AD, LEAROYD B, PEAK H. The treatment of hypercholesterolaemia by MER-29. Med J Aust. 1961 Dec 9;48(2):938–943. [PubMed]
  • KOUNTZ WB. Clinical observations on the effects of MER-29. Prog Cardiovasc Dis. 1960 May;2:541–543. [PubMed]
  • LECKERT JT, MCHARDY GG, MCHARDY RJ, WELCH GE, CRADIC H. Clinical evaluation of MER-29 in the treatment of hypercholesterolemia associated with atherosclerosis. Prog Cardiovasc Dis. 1960 May;2:571–575. [PubMed]
  • LISAN P. Prognostic significance of triparanol (MER-29). Prog Cardiovasc Dis. 1960 May;2:618–621. [PubMed]
  • OAKS W, LISAN P, MOYER JM. Inhibition of cholesterol synthesis with the use of Mer-29. Arch Intern Med. 1959 Oct;104:527–531. [PubMed]
  • OAKS WW. Metabolic effects of MER-29. Prog Cardiovasc Dis. 1960 May;2:612–617. [PubMed]
  • PALOPOLI FP. Basic research leading to MER-29. Prog Cardiovasc Dis. 1960 May;2:489–491. [PubMed]
  • ROSENMAN RH, FRIEDMAN M. Observations on the effect of triparanol (MER-29) on the serum cholesterol of selected human subjects. Prog Cardiovasc Dis. 1960 May;2:605–611. [PubMed]
  • RUSKIN A, RUSKIN B. Effect of MER-29 (triparanol) on serum cholesterol, cholesterol esters and liver enzymes. Prog Cardiovasc Dis. 1960 May;2:624–630. [PubMed]
  • SACHS BA, WOLFMAN L. Studies of serum desmosterol levels in hypercholesteremic subjects treated with triparanol (MER-29). Am J Clin Nutr. 1961 Nov-Dec;9:760–763. [PubMed]
  • STEINBERG D, AVIGAN J, FEIGELSON EB. Identification of 24-dehydrocholesterol in the serum of patients treated with MER-29. Prog Cardiovasc Dis. 1960 May;2:586–592. [PubMed]
  • TORO J. Evaluation of the administration of MER-29 to a group of institutionalized patients at the St. Louis Chronic Hospital: a preliminary report. Prog Cardiovasc Dis. 1960 May;2:544–547. [PubMed]

Articles from Proceedings of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press